Debridement and corpectomy via single posterior approach to treat pyogenic spondylitis after vertebral augmentation.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968565 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2474 (Electronic) Linking ISSN: 14712474 NLM ISO Abbreviation: BMC Musculoskelet Disord Subsets: MEDLINE

Original Publication: London : BioMed Central, [2000-

Spinal Fractures* ; Spinal Fusion* ; Spondylitis*; Debridement ; Humans ; Lumbar Vertebrae ; Spine ; Thoracic Vertebrae ; Treatment Outcome

Background: Infection after vertebral augmentation (VA) often limits the daily activities of patients and even threatens their life. The operation may be one of the effective treatments if the patient suffers from intolerable severe pain, neurological deficits, and damage to spinal stability. This study aimed to investigate the clinical efficacy of the treatment of pyogenic spondylitis after vertebral augmentation (PSVA) with Single posterior debridement, vertebral body resection, and intervertebral bone graft fusion and internal fixation (sPVRIF).
Methods: The study was performed on 19 patients with PSVA who underwent VA at 4 hospitals in the region between January 2010 and July 2020. Nineteen patients were included. Among them, 16 patients underwent sPVRIF to treat the PSVA.
Results: A total of 2267 patients underwent VA at 4 hospitals in the region. Of the 19 patients with postoperative PSVA, suppurative spondylitis was misdiagnosed as an osteoporotic vertebral fracture(OVF) in 4 patients and they underwent VA. Besides osteoporosis, 18 patients had other comorbidities. The average interval between the first surgery and the diagnosis of PSVA was 96.4 days. Of the 19 patients, 16 received surgical treatment. The surgical time was 175.0±16.8 min, and the intraoperative blood loss was 465.6±166.0 mL. Pathogenic microorganisms were cultured in 12 patients.
Conclusion: PSVA is a severe complication that can even threaten the life of the patients. sPVRIF may be one of the effective treatments if the patient suffers from intolerable severe pain, neurological deficits, and damage to spinal stability.

J Int Med Res. 2018 Feb;46(2):916-924. (PMID: 29239241)
Spine J. 2015 Jun 1;15(6):e1-6. (PMID: 25720730)
Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:155. (PMID: 29324925)
Medicine (Baltimore). 2016 Mar;95(11):e2940. (PMID: 26986102)
J Neurosurg Spine. 2008 May;8(5):405-12. (PMID: 18447685)
J Neurosurg Spine. 2006 Jul;5(1):86-9. (PMID: 16850965)
Neurosurgery. 1991 Jun;28(6):789-91. (PMID: 2067600)
Spine J. 2016 Oct;16(10):e659-e662. (PMID: 26961197)
Spine J. 2014 Jul 1;14(7):1366. (PMID: 24938910)
Arch Osteoporos. 2018 Apr 27;13(1):47. (PMID: 29704173)
Neurosurg Focus. 2004 Dec 15;17(6):E6. (PMID: 15636576)
Joint Bone Spine. 2006 Dec;73(6):753-5. (PMID: 16997600)
Eur Spine J. 2003 Dec;12(6):606-12. (PMID: 12961081)
Spine (Phila Pa 1976). 2004 May 15;29(10):E209-11. (PMID: 15131456)
BMC Infect Dis. 2018 Nov 12;18(1):555. (PMID: 30419832)
Spine J. 2013 Dec;13(12):1809-17. (PMID: 23880354)
Spine (Phila Pa 1976). 2006 Oct 15;31(22):E859-62. (PMID: 17047535)
Spine (Phila Pa 1976). 2006 Sep 15;31(20):E770-3. (PMID: 16985448)
Clin Orthop Surg. 2010 Dec;2(4):203-8. (PMID: 21119935)
Orthopedics. 2011 Nov 09;34(11):e788-92. (PMID: 22049968)
Korean J Spine. 2012 Mar;9(1):28-31. (PMID: 25983785)
Patient Saf Surg. 2008 Jan 15;2:2. (PMID: 18271950)
Neurochirurgie. 2008 Aug;54(4):551-5. (PMID: 18571206)
Clin Neurol Neurosurg. 2017 Jan;152:23-27. (PMID: 27866033)
Neurochirurgie. 1987;33(2):166-8. (PMID: 3600949)
J Bone Joint Surg Br. 2006 Jun;88(6):765-70. (PMID: 16720771)

Keywords: Clinical efficacy; Debridement; Pyogenic spondylitis; Single posterior approach; Vertebral augmentation

Date Created: 20210627 Date Completed: 20210629 Latest Revision: 20210701

20221213

PMC8236162

10.1186/s12891-021-04478-0

34174863